Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,712.73 -234.20 (-0.60%) Hang Seng
19,350.60 +129.98 (+0.68%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
70,237.02 -745.63 (-1.05%) CMC Crypto 200
1,526.60 +38.06 (+2.56%)
MDxHealth SA (0O8G.L)
- GlobeNewswire
Mdxhealth to Present at Upcoming Investor Conferences
Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024. William Blair 44th Annual Growth Stock ConferencePresentation: Wednesday, June 5, at 5:00pm ETWebcast: https://wsw.com/webcast/blair97/mdxh/1942906 Jefferies Global
- GlobeNewswire
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first qu
- GlobeNewswire
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk
